![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0013.png)
Notes:
Volume 6, Issue 4 (Suppl)
Clin Pharmacol Biopharm, an open access journal
ISSN: 2167-065X
Page 67
Euro Biopharma & Ethnopharmacology 2017
November 09-11, 2017
&
6
th
International Conference and Exhibition on
November 09-11, 2017 Vienna, Austria
4
th
EUROPEAN BIOPHARMA CONGRESS
PHARMACOLOGY AND ETHNOPHARMACOLOGY
Joint Event
Novel chemosensitizing effects for crocin and flavocoxid in a mouse eac-tumor model: cellular and
molecular triggers
Abdalla M El-Mowafy, Eman Said, Nehal M Elsherbiny, Rania R Abdelaziz
and
Marwa A Zaki
Mansoura University, Egypt
Purpose:
We evaluated the sole anddoxorubicin(doxo)-combinedchemotherapeutic andsurvival-effectsof thephytomedicines;
flavocoxid (flvcox) and crocin, using a mouse-Ehrlich-Ascites-Carcinoma-solid-tumor-model (EAC).
Methods:
We analyzed tumor-burden, animal-survival, redox status, and levels of mediators for tumorigenesis/inflammation,
host-immunity (serum-TNF-
α
and -IL-10) and tumor-apoptosis (Caspase-3-expression).
Results:
EAC-bearing-mice had significantly-raised serum-TNF-
α
and tumor-lipid-peroxide (MDA) levels, but reduced
serum-IL-10 levels and total-serum antioxidant-capacity (TAC), thereby inducing animal-fatalities after 3-weeks. Crocin
administration significantly-shrank tumor-mass, -reduced tumor-MDA and serum-TNF-
α
levels; but -raised serum-IL-10,
-TAC and tumor-caspase-3-levels; ultimately augmenting animal-survival. Furthermore, crocin appreciably optimized all
responses to doxo to markedly extend animal-survival. Flvcox had similar but less-prominent effects than crocin.
Conclusions:
Results reveal that: 1)-Doxo elicits superb cytotoxicity but lesser cytokine-, redox- and animal rescuing-profiles;
2)-Crocin and flvcox achieve significant-sole and -combined chemotherapeutic and animal-survival effects by modifying
cytokine levels, optimizing redox-potential and promoting tumor apoptosis.
aelmowafy@yahoo.comAbdalla M El-Mowafy et al., Clin Pharmacol Biopharm 2017, 6:4(Suppl)
DOI: 10.4172/2167-065X-C1-026